Martin Guscott, Director of Xenon Life Sciences Ltd. Consultancy in Medical and Clinical Affairs and Vice President Medical Affairs of Resonance, shared a post on LinkedIn:
“Please join the Global Neuroblastoma Meeting on Thursday to hear from Dr Brian D Crompton on “Detection of somatic structural variants enables quantification and characterization of circulating tumor DNA in children with solid tumors”.
Attendance is free for healthcare professionals and academic researchers.”
